Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P34059

UPID:
GALNS_HUMAN

ALTERNATIVE NAMES:
Chondroitinsulfatase; Galactose-6-sulfate sulfatase; N-acetylgalactosamine-6-sulfate sulfatase

ALTERNATIVE UPACC:
P34059; Q86VK3

BACKGROUND:
The enzyme N-acetylgalactosamine-6-sulfatase, also referred to as Chondroitinsulfatase, plays a pivotal role in the metabolic pathways that break down glycosaminoglycans, substances vital for the structural integrity of cartilage, connective tissues, and the cornea.

THERAPEUTIC SIGNIFICANCE:
Its deficiency causes Mucopolysaccharidosis 4A, a disorder with significant morbidity, impacting skeletal development and vision, yet sparing cognitive function. Advancements in understanding this enzyme's role offer promising avenues for developing novel therapeutic interventions, potentially transforming the management of this and related lysosomal storage diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.